Kyverna Therapeutics looks all the more likely to win the first FDA approval for a CAR-T therapy in an autoimmune disease ...

Kyverna has previously reported positive midstage data with miv-cel in generalised myasthenia gravis (gMG), another ...

The Ultimate Facial is the house blockbuster: a 90-minute, £480 treatment that combines Augustinus Bader’s signature Method ...

Kyverna shares Phase 2 data showing single-dose CAR-T improved mobility and reduced disability in stiff person syndrome.

Miv-cel was well-tolerated, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) observed. Grade 3/4 neutropenia, a known adverse event ...

Kyverna Therapeutics said on Monday its experimental cell therapy ‍for treating patients with a rare movement disorder met the main goal of a mid-stage study, sending ‌its shares surging ‌20% in ...

Before understanding how genetics plays its role in muscle Building, let’s see what the basics of genetics are. So, at the ...

Shares of Kyverna Therapeutics climbed after the company said it would disclose topline results from a mid-stage trial of its treatment for stiff person syndrome. The stock rose 20%, to $10.50, in ...

The Grinch is a timeless Christmas character, but what did his skeleton, muscles, and brain look like? An anatomist ponders.

Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel ...

Stiff person syndrome refers to a rare autoimmune neurological disorder that most commonly causes muscle stiffness and painful spasms that come and go and can worsen over time. There is currently no ...